Picard Medical / SynCardia Featured in Interview Series with The Mullings Group
Rhea-AI Summary
Picard Medical (NYSE American: PMI) and SynCardia were featured in a two-part interview series with Joe Mullings that highlights total artificial heart therapy, the advanced heart failure market, and the company’s next‑generation platform development. Picard Medical CEO Patrick N.J. Schnegelsberg discusses SynCardia clinical use and the fully implantable Emperor Total Artificial Heart.
Positive
- None.
Negative
- None.
News Market Reaction – PMI
In the Apr 29 session, PMI gained 5.57%, reflecting a notable positive market reaction. Argus tracked a peak move of +58.2% during that session. Argus tracked a trough of -17.4% from its starting point during tracking. Our momentum scanner triggered 38 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 107.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Earnings update | Positive | +6.9% | Preliminary Q1 2026 revenue up 79.9% year over year to $1.1 million. |
| Apr 16 | Product platform update | Positive | -3.1% | Announcement to present next‑generation fully implantable total artificial heart at ISHLT. |
| Apr 15 | Clinical case highlight | Positive | -1.8% | Bridge‑to‑transplant success at Texas Children’s Hospital using SynCardia Total Artificial Heart. |
| Apr 02 | Conference keynote | Positive | -9.4% | COO keynote at Arizona Tech Week focused on next‑generation TAH technology and access. |
| Apr 01 | Patient-focused event | Neutral | +1.0% | Participation in Voice of the Patient event highlighting advanced heart failure experiences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news and events often saw muted or negative price reactions, even when updates highlighted growth, technology advances, or clinical milestones, with only some earnings and investor-focused items aligning positively.
Over the last month, PMI has issued multiple updates on clinical use of the SynCardia Total Artificial Heart, next‑generation Emperor platform development, and investor- and patient-focused events. News on Apr 22 reported strong preliminary Q1 2026 revenue growth and was followed by a 6.91% gain. In contrast, several technology and conference announcements in early April produced modest declines, indicating that operational or clinical visibility has not consistently translated into positive price reactions prior to this media-focused interview news.
Key Terms
total artificial heart medical
advanced heart failure medical
end-stage biventricular failure medical
bridge to transplant medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development –
TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems LLC (“SynCardia”), maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, announced today it has been featured in a two-part interview series with Joe Mullings, Chairman and Chief Executive Officer of The Mullings Group Companies, a premier global executive search firm specialized in the MedTech, HealthTech, and Life Sciences industries. Filmed, edited, and produced by Dragonfly, A TMG Company, the series features an in-depth discussion with Picard Medical Chief Executive Officer, Patrick N.J. Schnegelsberg, focused on advanced heart failure and the role of total artificial heart technology in patients with end-stage biventricular failure.
The discussions outline the clinical use of the SynCardia Total Artificial Heart, the only U.S. FDA-approved total artificial heart, which replaces the pumping function of the native heart, and is used as a bridge to transplant for patients awaiting donor organs. Mr. Schnegelsberg also highlights the Company’s innovation strategy, including development of its next generation fully implantable platform, the Emperor Total Artificial Heart, designed to improve patient mobility and expand access to therapy.
“For patients with end-stage biventricular failure, total artificial heart therapy is often the only viable option,” Mr. Schnegelsberg emphasized during the first interview. “We are delivering that solution today, while advancing a fully implantable platform designed to expand access and redefine long term mechanical heart replacement.”
The interviews also examine broader dynamics in the heart failure treatment landscape, including the limitations of existing therapies, the gap between patient demand and available treatment options, and ongoing innovation in the space.
The full interview series is available for replay at these links:
https://www.youtube.com/watch?v=S2TdsPB5wuU
https://www.youtube.com/watch?v=ziLhhWEamN0
About The Mullings Group Companies
Founded in 1992, The Mullings Group is an executive search, media/marketing, and advisory firm focused on medtech, healthtech, and life sciences. The firm has completed more than 9,000 placements across over 900 companies globally. The firm provides executive search services across all levels, from individual contributors to C-suite and board roles, and supports hiring initiatives ranging from targeted placements to large scale team builds. Its advisory services include organizational design, succession planning, and strategic initiatives aligned with client objectives. Through Dragonfly, its media and marketing company, The Mullings Group develops employer branding, thought leadership, and positioning strategies aimed at attracting talent and capital. Headquartered in Delray Beach, Florida, the firm operates offices across the United States, Canada, the United Kingdom, Israel, and Asia Pacific.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the STAH is the most widely used and extensively studied artificial heart in the world. For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. These statements include, but are not limited to, statements regarding the development and design of the Emperor Total Artificial Heart. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Additional information about the Company, including risk factors that may affect the Company’s business, financial condition, and results of operations, is contained in the Company's filings with the SEC, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available free of charge on the SEC’s website at http://www.sec.gov and on the Company's investor relations website at https://picardmedical.com/.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com
Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com
General/Media
Brittany Lanza
blanza@syncardia.com
